The Food and Drug Administration has approved a new drug, Cobenfy, for schizophrenia that is said to have fewer side effects than current medications. This has been a major development for patients like Tiffany who have struggled with severe side effects from traditional antipsychotic drugs. Tiffany shares her personal experience and how this new medication gives her hope for a better quality of life.
Schizophrenia: New Drug Approved by FDA Offers Hope for Patients
Background
Schizophrenia is a severe mental disorder characterized by hallucinations, delusions, disorganized thinking, and social withdrawal. Antipsychotic medications have been the mainstay of treatment for schizophrenia, but they often cause significant side effects, including movement disorders, metabolic problems, and cognitive impairment.
FDA Approves New Drug for Schizophrenia
In February 2023, the US Food and Drug Administration (FDA) approved a new medication called Cobenfy (asenapine sublingual tablet) for the treatment of schizophrenia. Cobenfy is a novel antipsychotic that is designed to have fewer side effects than traditional medications.
Trials have shown that Cobenfy is effective in reducing the symptoms of schizophrenia and improving overall functioning. Unlike other antipsychotics that are given as injections or tablets, Cobenfy is administered sublingually (under the tongue), which allows for faster absorption and a potential reduction in side effects.
Patient Perspective
For patients like Tiffany, who has struggled with severe side effects from traditional antipsychotic drugs, Cobenfy offers a beacon of hope. Tiffany has experienced significant improvement in her symptoms and quality of life since starting Cobenfy.
"It's like a weight has been lifted off my shoulders," said Tiffany. "I'm able to think more clearly, I'm more social, and I'm finally starting to feel like myself again."
Top 5 FAQs
1. What are the potential benefits of Cobenfy over other antipsychotics?
Cobenfy is designed to have fewer side effects, including movement disorders, metabolic problems, and cognitive impairment.
2. How is Cobenfy administered?
Cobenfy is administered sublingually, which means it is placed under the tongue. This allows for faster absorption and a potential reduction in side effects.
3. What are the common side effects of Cobenfy?
The most common side effects of Cobenfy include headache, nausea, vomiting, dizziness, and drowsiness.
4. Is Cobenfy approved for use in all patients with schizophrenia?
While Cobenfy is generally well-tolerated, it may not be appropriate for all patients with schizophrenia. It is important to discuss your individual needs with your healthcare provider.
5. What is the long-term outlook for patients taking Cobenfy?
Studies are ongoing to determine the long-term safety and efficacy of Cobenfy. However, the short-term results have been promising, and patients like Tiffany are hopeful for a brighter future.
WHO has released its first-ever global guideline on managing sickle cell disease (SCD) during pregnancy, highlighting the dangers faced by women and their babies. SCD is an inherited blood disorder with potentially fatal consequences, and the health risks intensify during pregnancy. The new guideline aims to improve outcomes for pregnant women with SCD and calls for more investment in evidence-based treatments and disease awareness. With SCD on the rise globally, increasing numbers of maternity care providers need to be equipped to handle its challenges.
On Thursday, March 19 at 5:01 a.m. ET, the vernal equinox or the first day of spring will take place in the Northern Hemisphere. This marks the beginning of the season of longer days and warmer weather as the sun's rays fall directly on the equator. Despite popular belief, day and night are not exactly the same length on the equinox due to atmospheric refraction. The summer and winter solstices and the autumnal equinox also have significant impacts on the Earth's tilt and the length of daylight hours.
A new, inexpensive Arduino-based logger has been developed for accurately mapping the depths of water bodies. By using budget-friendly hardware such as a GPS module and an SD card, combined with a standard NMEA capable echolot sounder, this device is accessible and practical for scientists, recreational enthusiasts, and more. With the added use of Python and matplotlib, users can now easily transform the collected data into detailed depth maps, revealing vital information about water levels and shallow spots in various environments.
After a 28-hour journey through space, Group Captain Shukla has become the first Indian to board the International Space Station (ISS). Accompanied by three other astronauts from the Axiom-4 mission, the ISS is now hosting a total of 11 people. Shukla was welcomed with hugs by the astronauts already stationed at the ISS and presented with the astronaut number 634. As the pilot of the mission, Shukla was given a number ahead of his fellow rookie astronauts and was offered a liquid diet to refresh himself before exploring the six-bedroom facility in space.
Indian astronaut Shubhanshu Shukla has successfully docked with the International Space Station on the Axiom Mission 4. This marks a proud milestone in Indian space history, as Shukla becomes the first Indian to reach the ISS. The docking process involved intricate procedures, and upon arrival, Shukla and his crew were welcomed with warm hugs and will conduct various experiments during their 14-day mission on the ISS.
After a 28-hour journey, Indian astronaut Shubhanshu Shukla and three other astronauts were welcomed onto the International Space Station (ISS) by the expedition team. Shukla expressed his gratitude and excitement for the 14-day mission, where they will conduct scientific experiments and interact with people on Earth. He also shared his amazement at the view and the warm welcome he received from the ISS crew.
Indian astronaut Shubhanshu Shukla has been launched to the International Space Station as part of the Axiom 4 mission aboard the SpaceX Dragon spacecraft. The spacecraft is currently en route to the ISS and is expected to dock with the Harmony module on June 26. The mission, led by Peggy Whitson, will last for two weeks and include scientific research, outreach activities, and commercial projects. Shubhanshu Shukla is joined by mission specialists from ESA and HUNOR. Get to know all about this historic mission carrying an Indian astronaut to space after 40 years.
After multiple delays, the Axiom-4 mission has finally launched with Indian astronaut Shubhanshu Shukla onboard for an important space mission. The spacecraft, carrying Shukla as the pilot along with three other astronauts, will dock at the International Space Station in a few hours. This joint mission between India, Poland, and Hungary marks a significant step in international human spaceflight collaborations and showcases India's ambitions in global space exploration. Shukla's journey not only symbolizes India's return to human spaceflight but also propels the country's human space program to new heights.
Group Captain Shubhanshu Shukla, a native of Lucknow, is commanding the Axiom-4 Mission to the International Space Station, breaking barriers for India in space exploration. As his family watches the live broadcast of the historic event, they express their pride and excitement for Shukla's role as a key member of the international crew. Along with Commander Peggy Whitson, Shukla and the team will carry out groundbreaking research and outreach during their 14-day mission.
The successful launch of the Axiom Mission 4, carrying astronauts from India, Hungary, Poland, and the US, has sparked celebrations across the country. Group Captain Shubhanshu Shukla, the Indian astronaut on board, has received wishes and cheers from prominent leaders, including President Droupadi Murmu and Prime Minister Narendra Modi. The mission is expected to lead to new frontiers in scientific studies and space exploration, showcasing the enduring partnership between NASA and ISRO.